Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Adderall XR Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
Louis SanfilippoJune 30, 2008
Lundbeck Reveals Mechanism of Action of its “Mixed Serotonin Modulator and Stimulator” Antidepressant LuAA21004
Analysis of: Interim report for the first quarter of 2008 - strong growth in sales and profits | www.lundbeck.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report.   Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...
June 30, 2008
If you've done everything else, there is nothing else
Analysis of: Doctors Say Medication Is Overused in Dementia | www.nytimes.com
Author: GLG Expert Contributor
We need to look to the cause of why we prescribe antipsychotics to patients with dementia.  We have very few tools to use and sometimes these drugs are a necessity.
June 23, 2008
We can't afford to practice the "best" medicine
Analysis of: Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Author: GLG Expert Contributor
This article clearly describes the Catch-22 in which most doctors, except for those employed by the large institutions, find themselves.  We cannot afford to practice the "best" medicine, and yet, if we could, we might well make fewer errors and make medical care for our patients more seamless. ...
Daniel WynnJune 5, 2008
Novartis and Multiple Sclerosis: A Major Commitment
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...
Daniel WynnJune 2, 2008
Abbott's ABT-089 --Much More than a Treatment for ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Louis SanfilippoMay 21, 2008
BrainCells Novel Antidepressant: Targeting Neurogenesis but not Serotonin?
Analysis of: BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety | www.medicalnewstoday.com
Author: Louis Sanfilippo, President, LCS Group, LLC
It’s not clear just how BrainCells’ BCI-540 works but the company claims the drug acts by way of promoting neurogenesis without an effect on serotonin neurotransmission.   While SSRI’s also promote neurogenesis, a downstream effect believed to favorably impact mood and anxiety, they obviously...
May 14, 2008
Abbot's potentially interesting avenue of approach to adult ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
This is a potentially interesting alternative to current ADHD stimulant treatment. There is, I believe, existing literature on the efficacy of nicotine patches in the treatment of severe,otherwise intractable ADHD in children, which would seem to support these results. Of course, much work remains to...
Louis SanfilippoMay 13, 2008
Abbott Targets Adult ADHD with Nicotinic Drug, Shows Strong CNS Pipeline
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Abbott’s Neuronal Nicotinic Receptor (NNR) partial agonist platform is an innovative target for ADHD and potentially other CNS disorders.  The Phase II data on ABT-089 suggests efficacy for adult ADHD with good safety/tolerability.  NNRs will not have the kind of effect size seen with stimulants...
May 12, 2008
Possible wave of the future---or the present
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
NNR's are being heavily studied for several uses and are looking promising.
May 12, 2008
The pros and cons of Strattera driving marketing
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
Eli Lilly needs to find a compelling niche for Strattera since, in the treatment of ADHD, it is viewed as a less effective, though safer (because it cannot be abused), alternative to stimulants.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 215

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747